GABRA4
ENSG00000109158
Target class
Ion channel
Chromosome
4
Approved drugs
56
Clinical candidates (approved and in development)
68
- Approved drugs
- 56
- Clinical candidates (approved and in development)
- 68
- Chemical probe available
- No
- Target name
- GABRA4
- Gene name
- Gamma-aminobutyric acid type A receptor subunit alpha4
- Gene symbol
- GABRA4
- Protein name
- Gamma-aminobutyric acid receptor subunit alpha-4 (GABA(A) receptor subunit alpha-4) (GABAAR subunit alpha-4)
- Gene biotype
- Protein coding
- Gene family
- Gamma-aminobutyric acid type A receptor subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 14
- Highest tissue expression
- 10.72
- Tissue specificity (Gini)
- 0.815
- Tissue specificity (tau)
- 0.917
- KEGG gene identifiers
- hsa:2557
- Reactome pathways
- R-HSA-977443
- Protein interaction confidence
- 0.844294
- Protein interaction partners
- 17
- End position
- 46993581
- Start position
- 46918900
- Chromosome
- 4
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Postsynaptic cell membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 35355020
- Tissue specificity (tau)
- 0.917312
- Expression inequality (Gini)
- 0.814731
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 10.72
- Brain - Caudate (basal ganglia)
- 7.97
- Brain - Frontal Cortex (BA9)
- 7.74
- Brain - Cortex
- 5.11
- Brain - Putamen (basal ganglia)
- 4.84
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)10.72
- Brain - Caudate (basal ganglia)7.97
- Brain - Frontal Cortex (BA9)7.74
- Brain - Cortex5.11
- Brain - Putamen (basal ganglia)4.84
- Brain - Anterior cingulate cortex (BA24)4.52
- Brain - Amygdala2.65
- Artery - Tibial1.88
- Artery - Coronary1.81
- Brain - Hypothalamus1.77
- Brain - Hippocampus1.71
- Pituitary1.6
- Brain - Cerebellum1.38
- Heart - Left Ventricle1.29
- Brain - Cerebellar Hemisphere0.68
- Brain - Substantia nigra0.58
- Testis0.2
- Skin - Not Sun Exposed (Suprapubic)0.14
- Artery - Aorta0.14
- Brain - Spinal cord (cervical c-1)0.12
- Small Intestine - Terminal Ileum0.12
- Esophagus - Mucosa0.1
- Skin - Sun Exposed (Lower leg)0.08
- Adipose - Subcutaneous0.08
- Colon - Sigmoid0.06
And 29 more, listed on the interactive page.
- GO:0007214
- GO:1902476
Cellular components
- GO:0005886
Molecular functions
- GO:0008503
decreased cardiac contractility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased cardiac contractility
- central nervous system
- cardiovascular
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- central nervous system
- cardiovascular
PubMed 28216264decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
- central nervous system
- cardiovascular
PubMed 28216264decreased sleep
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased sleep
- central nervous system
- cardiovascular
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- central nervous system
- cardiovascular
PubMed 28216264decreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
- central nervous system
- cardiovascular
PubMed 28216264increased eating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased eating
- central nervous system
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- central nervous system
- cardiovascular
PubMed 28216264muscle relaxation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: muscle relaxation
- central nervous system
- cardiovascular
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- central nervous system
- cardiovascular
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- central nervous system
- cardiovascular
PubMed 28216264convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: convulsions
- central nervous system
- cardiovascular
PubMed 28216264decreased anxiety
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased anxiety
- central nervous system
- cardiovascular
PubMed 28216264increased respiratory rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased respiratory rate
- central nervous system
- cardiovascular
PubMed 28216264ataxia
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: ataxia
- central nervous system
- cardiovascular
PubMed 28216264increased cardiac output
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased cardiac output
- central nervous system
- cardiovascular
PubMed 28216264increased sleep
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased sleep
- central nervous system
- cardiovascular
PubMed 28216264
Related records
Trials (3,914)
- "Chou's Tiaoshen" Acupoints for Short-term Insomnia.
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
- 1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia
- 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
- 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
- 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion
- 50% Effective Concentration of Sevoflurane for Immobility
- 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A Better Choice for Patients Undergoing Endovascular Coil Embolization
- A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
- A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects
Drugs (78)
- ABP-700 GABA-A receptor; anion channel agonist
- Acamprosate GABA-A receptor; anion channel positive modulator
- Acamprosate calcium GABA-A receptor; anion channel positive modulator
- Adipiplon GABA-A receptor; anion channel partial agonist
- Alprazolam GABA-A receptor; anion channel positive allosteric modulator
- Brexanolone GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
- Butalbital GABA-A receptor; anion channel positive allosteric modulator
- Cenobamate GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
- Cipepofol GABA-A receptor; anion channel agonist
- Clobazam GABA-A receptor; anion channel positive allosteric modulator
- Clomethiazole GABA-A receptor; anion channel positive allosteric modulator
- Clonazepam GABA-A receptor; anion channel positive allosteric modulator
- Clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator
- Clorazepic acid GABA-A receptor; anion channel positive allosteric modulator
- Clotiazepam GABA-A receptor; anion channel positive allosteric modulator
- Darigabat GABA-A receptor; anion channel agonist